HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

doxorubicin-DNA

complex of above two compounds to reduce toxicity of doxorubicin

Also Known As:

DNA-adriamycin complex; adriamycin-DNA

Networked: 25 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cutts, Suzanne M: 4 articles (02/2010 - 02/2003)
2.	Nudelman, Abraham: 4 articles (02/2010 - 02/2003)
3.	Phillips, Don R: 4 articles (02/2010 - 02/2003)
4.	Rephaeli, Ada: 4 articles (02/2010 - 02/2003)
5.	Hua, Haiying: 2 articles (01/2022 - 11/2016)
6.	Huang, Weiwei: 2 articles (01/2022 - 11/2016)
7.	Li, Shasha: 2 articles (01/2022 - 11/2016)
8.	Liu, Dan: 2 articles (01/2022 - 11/2016)
9.	Song, Lili: 2 articles (01/2022 - 11/2016)
10.	Sun, Pengchao: 2 articles (01/2022 - 11/2016)

Related Diseases

1.	Adenocarcinoma 03/01/1977 - "The comparative toxicity and therapeutic efficacy of adriamycin and the adriamycin-DNA complex in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma."
2.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/01/1979 - "Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma." 01/01/1991 - "In the light of previous findings that treatment of leukemia patients with DNA-linked doxorubicin gave higher doxorubicin concentrations in leukemic cells than treatment with doxorubicin alone, the Leukemia Group of Middle Sweden performed a randomized clinical trial to compare the effects of doxorubicin and doxorubicin-DNA in patients with acute non-lymphoblastic leukemia. " 01/01/1979 - "Treatment with daunorubicin-DNA (DNR-DNA) or adriamycin-DNA (ADM-DNA) has been evaluated in acute lymphoblastic leukemia of childhood (ALL), acute nonlymphoblastic leukemia (ANLL) and bronchogenic carcinoma (BC). "
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/1991 - "A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia." 01/01/1979 - "Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma." 01/01/1979 - "Treatment with daunorubicin-DNA (DNR-DNA) or adriamycin-DNA (ADM-DNA) has been evaluated in acute lymphoblastic leukemia of childhood (ALL), acute nonlymphoblastic leukemia (ANLL) and bronchogenic carcinoma (BC). "
4.	Bronchogenic Carcinoma 06/01/1978 - "Adriamycin and adriamycin--DNA in inoperable bronchogenic carcinoma. " 01/01/1979 - "Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma." 01/01/1979 - "Treatment with daunorubicin-DNA (DNR-DNA) or adriamycin-DNA (ADM-DNA) has been evaluated in acute lymphoblastic leukemia of childhood (ALL), acute nonlymphoblastic leukemia (ANLL) and bronchogenic carcinoma (BC). "
5.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/15/1990 - "In a previous study we suggested that, in addition to the reduced Adriamycin accumulation, part of the resistance in an Adriamycin-resistant human small cell lung carcinoma cell line (GLC4/ADR) could be explained by supposing a changed Adriamycin-DNA-topoisomerase II (Topo II) interaction. "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	daunorubicin-DNA
3.	Type II DNA Topoisomerases (Topoisomerase II)
4.	trioctyl phosphine oxide (TOPO)
5.	Gold
6.	DNA (Deoxyribonucleic Acid)
7.	LDL Receptors (LDL Receptor)
8.	Formaldehyde (Formol)
9.	DNA Adducts
10.	Complementary DNA (cDNA)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics